Sparks commentary - OSE Immunotherapeutics

Healthcare

Sparks - OSE Immunotherapeutics

More on this equity
OSE-Immunotherapeutics_resized
OSE Immunotherapeutics (PAR: OSE) confirms new CEO
Published by Arron Aatkar, PhD

OSE Immunotherapeutics has announced that Marc Le Bozec will transition form interim CEO (which was effective from 2 October 2025) to permanent CEO (effective immediately). The decision was made based on a detailed review of internal and external candidates, and upon recommendation of the Nomination and Compensation Committee. Marc Le Bozec is committed to leading the company in its goals to deliver novel immunotherapies in the fields of immuno-oncology and immuno-inflammation, with a focus on precision medicine and patient centric clinical development.

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.